| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d34d04294f69e603272e30f2cb660d1e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2014-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_668b8853bd758cb7e635055c92b55a6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec5462da83a380688a0eaaf61656ae5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08d8b1455670edc232bd7765bfa83867 |
| publicationDate |
2018-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9993460-B2 |
| titleOfInvention |
Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
| abstract |
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11147800-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11730750-B2 |
| priorityDate |
2013-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |